OT: Biovail
Blade:
The only partner that can rest assured that their program is going to be sustained is Alexza. Not that all the others will be culled, but any one--or two--of them could be deleted. Pimavanserin, having had Phase III started, may be less at risk than earlier-stage programs. CX717 benefits by fitting into the hospital sales framework, but it is vulnerable due to its early clinical stage. It is not clear to me how the balance of power now stands within the merging company, which champions of which programs still wield clout. But I don't know the Valeant CEO, other than by the fact he chose to exit CNS entirely a year or two ago, so I don't know his thinking on this. I think the neuroprotection programs may be most at risk.
NeuroInvestment
Market Data 
Markets 
AI
